查詢結果分析
相關文獻
- Neoadjuvant Concurrent Chemoradiotherapy in Treating Locally Advanced Rectal Cancer
- Oxaliplatin-based Neo-adjuvant Concurrent Chemo-radiotherapy in Treating Locally Advanced Lower Rectal Cancer
- Outcomes of Neoadjuvant Chemoradiation Therapy for Locally Advanced Rectal Cancer: The Effect of Preoperative Chemoradiotherapy Followed by Additional Chemotherapy on Advanced Rectal Cancer
頁籤選單縮合
題名 | Neoadjuvant Concurrent Chemoradiotherapy in Treating Locally Advanced Rectal Cancer=局部侵犯性直腸癌之術前輔助性電化療 |
---|---|
作者 | 涂嘉明; 王輝明; 陳周斌; 趙德馨; 馬秀峰; | 書刊名 | Journal of the Chinese Medical Association |
卷期 | 72:4 2009.04[民98.04] |
頁次 | 頁179-182+CA34 |
分類號 | 416.245 |
關鍵詞 | 局部侵犯性直腸癌; 術前輔助性電化療; RO切除率; Locally advanced rectal cancer; Neoadjuvant concurrent chemoradiotherapy; R0 resection; |
語文 | 英文(English) |
英文摘要 | Background: Colorectal cancer is a common cancer and a major cause of morbidity and mortality worldwide. Middle to lower rectal cancer, a challenge for surgeons, is problematic. Neoadjuvant concurrent chemoradiotherapy (CCRT), introduced in the last decade, leads the local control of advanced rectal cancer to a high percentage of R0 resection (margin negative under microscopic examination) and a low recurrence rate. Methods: From January 2005 to June 2007, 46 patients with locally advanced rectal cancer who received neoadjuvant CCRT were included. Factors including disease-free survival time, overall survival time, local recurrence, metastasis, and postoperative complications were evaluated retrospectively. Response was defined according to Mandard’s classification, in which TRG1 is no residual tumor and TRG2–3 is 50–100% tumor shrinkage. Results: In this series, 3 patients who did not receive post-CCRT curative resection were excluded. The remaining 43 patients (22 males, 21 females) had received curative surgery and were included. Thirty-four patients had tumor shrinkage, and the response rate was 79% (Mandard’s classification: TRG1–TRG3). The median follow-up time was longer than 1.5 years. Patients who responded to CCRT had lower local recurrence rates (5.9% vs. 55.6%; p = 0.002) and a greater curative resection rate (97.1% vs. 66.7%; p = 0.024). The complication rates of both groups were similar. Conclusion: Neoadjuvant CCRT gives locally advanced rectal cancer patients a more favorable result, with acceptable toxicity. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。